Ozempic side effects on TikTok: fear vs. actual clinical data

What did @adampotashapproach actually say?

This video is a collage of user comments about GLP-1 side effects, read aloud by the creator. The framing is clear from the jump: these drugs are dangerous and you should "do your research" before starting them. The creator reads testimonials describing gastroparesis, acute pancreatitis, a three-day coma, cancer scares from GI thickening, and severe muscle loss. One commenter claims to be an RN who got sick. Another says the drug "almost killed" a loved one. The creator wraps it up with "the list goes on and on" and a warning to read the label before starting anything.

To be fair, this is not a creator inventing claims. They are aggregating real patient experiences from comments. But aggregating scary anecdotes without any frequency or context is its own form of misleading communication, especially to a health-anxious audience who may be weighing whether to start a medication their doctor recommended.

Does the science back this up?

Some of it, yes. But the framing inflates rare risks into a pattern of near-certain harm, and that is not what the data shows.

Gastroparesis is a real concern. A 2023 JAMA study (Sodhi et al., JAMA, 2023) found that GLP-1 receptor agonist users had a significantly higher risk of gastroparesis compared to bupropion-naltrexone users, with an adjusted incidence rate ratio of 3.67. That is not nothing. But absolute risk matters: the incidence was still low in absolute terms, and the study population included people with and without diabetes.

Pancreatitis is listed in the prescribing information for semaglutide, and the FDA label does carry a warning. However, large meta-analyses have not confirmed a dramatically elevated risk in the general GLP-1 user population. A 2014 Cochrane review (Liu et al.) found no statistically significant increase in pancreatitis with GLP-1 agonists versus comparators in randomized trials. The picture is genuinely mixed, and the risk is real enough to monitor but not so large that it should be presented as near-inevitable.

Nausea, vomiting, and diarrhea are the most common side effects and are well-documented. In the SUSTAIN-6 trial (Marso et al., NEJM, 2016), GI events were the most frequent adverse effects, leading to discontinuation in a meaningful subset of patients. That is a legitimate thing to flag.

What did they get wrong (or right)?

They got the existence of these side effects right. They got the severity distribution completely wrong.

Reading a comment that says Ozempic caused a GI scan to show thickening "and they suspected cancer" without noting that cancer was not confirmed is irresponsible framing. Suspected cancer in a workup is not cancer. Presenting it as a drug consequence without a confirmed diagnosis misleads viewers into equating a differential diagnosis with an outcome.

The claim about a loved one being put "in a coma for three days" from pancreatitis is unverifiable. Severe pancreatitis can be life-threatening, that part is true. But presenting a single anecdote as evidence of a common outcome is a logical error, not a safety briefing.

The muscle loss concern is actually the most scientifically grounded piece here. Research published in Cell Metabolism (Wilding et al., 2021, and follow-up analyses) confirmed that a significant portion of weight lost on semaglutide is lean mass, not just fat. This is a real clinical consideration that is under-discussed in pro-Ozempic content. Credit where it is due.

What the creator consistently gets wrong is base rate. Side effects that affect 1-3% of users sound very different when you read ten horror stories back to back with no denominator.

What should you actually know?

GLP-1 medications have a real side effect profile that deserves honest discussion. The common ones, primarily GI symptoms, affect a substantial minority of users and cause discontinuation in some. The rare ones, including pancreatitis and gastroparesis, are serious and worth knowing about before you start.

But "do your research" followed by a string of worst-case anecdotes is not research. It is fear amplification. If you are considering a GLP-1 medication, the actual conversation to have is with a licensed prescriber who can review your personal GI history, your pancreatitis risk factors, and your goals. Screening questions matter. Dose titration matters. Monitoring matters.

The lean mass issue raised in this video is worth taking seriously. A 2023 analysis in the New England Journal of Medicine (Wilding et al., NEJM, 2023) noted that without resistance training, a significant portion of weight lost on semaglutide includes skeletal muscle. That is a real clinical concern, not a scare story, and it argues for combining GLP-1 therapy with structured exercise, not for avoiding the medication entirely.

Anyone experiencing severe or persistent vomiting, diarrhea, or abdominal pain on a GLP-1 should contact their prescriber promptly. Those symptoms warrant evaluation, not just powering through.